Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Axsome (AXSM) Posts Narrower-Than-Expected Q4 Loss
01:47pm, Wednesday, 02'nd Mar 2022
Axsome Therapeutics (AXSM) reports a narrower-than-expected Q4 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.
Axsome Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
12:00pm, Wednesday, 02'nd Mar 2022 GlobeNewswire
NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a virtual fireside chat at the Cowen 42 nd Annual Health Care Conference on Monday, March 7, 2022 at 10:30 AM Eastern Time.
Axsome Therapeutics (AXSM) Q4 2021 Earnings Call Transcript
10:30pm, Tuesday, 01'st Mar 2022 The Motley Fool
AXSM earnings call for the period ending December 31, 2021.
Why Axsome Therapeutics Stock Is Bolting Higher Today
07:13pm, Tuesday, 01'st Mar 2022 The Motley Fool
Investors appear to be convinced that AXS-05 will get a green light from the FDA soon.
Axsome Therapeutics, Inc.''s (AXSM) CEO Herriot Tabuteau on Q4 2021 Results - Earnings Call Transcript
04:37pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Axsome stock rises 9% as company eyes potential approval/launch of drugs in FY22
04:28pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Axsome Therapeutics <> stock rose following its Q4 results."2021 was a year of continued progress which has put us in a position to potentially launch two new…
Why Axsome Therapeutics Stock Is Bolting Higher Today
02:13pm, Tuesday, 01'st Mar 2022
Investors appear to be convinced that AXS-05 will get a green light from the FDA soon.
Axsome Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
12:00pm, Tuesday, 01'st Mar 2022 GlobeNewswire
Company to host conference call today at 8:00 AM Eastern
Axsome Therapeutics, Inc.'s (AXSM) CEO Herriot Tabuteau on Q4 2021 Results - Earnings Call Transcript
11:37am, Tuesday, 01'st Mar 2022
Axsome Therapeutics, Inc.'s (AXSM) CEO Herriot Tabuteau on Q4 2021 Results - Earnings Call Transcript
This Stock Could Soar by 195%, According to Wall Street
10:23am, Tuesday, 01'st Mar 2022
This company has several potential catalysts on the way.
Axsome Therapeutics Q4 2021 Earnings Preview
05:22pm, Monday, 28'th Feb 2022 Seeking Alpha
Axsome Therapeutics (NASDAQ:AXSM) is scheduled to announce Q4 earnings results on Tuesday, Mar. 1, before market open.Consensus EPS estimate is -$0.96.
Axsome Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
12:00pm, Tuesday, 15'th Feb 2022 GlobeNewswire
Axsome to host conference call and webcast on Tuesday, March 1, 2022 at 8:00 AM Eastern Time
Axsome Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
07:00am, Tuesday, 15'th Feb 2022
Axsome to host conference call and webcast on Tuesday, March 1, 2022 at 8:00 AM Eastern Time
Axsome Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
12:00pm, Friday, 11'th Feb 2022 GlobeNewswire
NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a virtual fireside chat at the 11 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 1:40 PM Eastern Time.
Axsome Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
07:00am, Friday, 11'th Feb 2022
NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorder
